KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$14.47 USD
-0.92 (-5.98%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.49 +0.02 (0.14%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for KalVista Pharmaceuticals, Inc falls in the month of April .
All items in Millions except EPS data.
4/30/24 | 4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 13 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 13 |
Selling & Adminstrative & Depr. & Amort Expenses | 140 | 111 | 97 | 58 | 53 |
Income After Depreciation & Amortization | -140 | -111 | -97 | -58 | -41 |
Non-Operating Income | 14 | 18 | 14 | 12 | 11 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -127 | -93 | -82 | -46 | -29 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -127 | -93 | -82 | -46 | -29 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -127 | -93 | -82 | -46 | -29 |
Depreciation Footnote | 4/30/24 | 4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -140 | -109 | -93 | -57 | -40 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 3 | 1 | 1 |
Income After Depreciation & Amortization | -140 | -111 | -97 | -58 | -41 |
Earnings Per Share Data | 4/30/24 | 4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 |
---|---|---|---|---|---|
Average Shares | 36.79 | 27.89 | 24.47 | 19.09 | 17.75 |
Diluted EPS Before Non-Recurring Items | -3.44 | -3.33 | -3.36 | -2.42 | -1.64 |
Diluted Net EPS (GAAP) | -3.44 | -3.33 | -3.36 | -2.42 | -1.64 |
Fiscal Year end for KalVista Pharmaceuticals, Inc falls in the month of April .
All items in Millions except EPS data.
4/30/24 | 1/31/24 | 10/31/23 | 7/31/23 | 4/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 48.46 | 33.15 | 29.75 | 29.10 | 31.73 |
Income After SG&A, R&D, and Dept/Amort Expenses | -48.46 | -33.15 | -29.75 | -29.10 | -31.73 |
Non-Operating Income | 3.81 | 4.12 | 2.10 | 3.78 | 5.42 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -44.65 | -29.03 | -27.65 | -25.32 | -26.31 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -44.65 | -29.03 | -27.65 | -25.32 | -26.31 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -44.65 | -29.03 | -27.65 | -25.32 | -26.31 |
Earnings Per Share Data | 4/30/24 | 1/31/24 | 10/31/23 | 7/31/23 | 4/30/23 |
---|---|---|---|---|---|
Average Shares | 43.59 | 34.72 | 34.57 | 34.41 | 34.34 |
Diluted EPS Before Non-Recurring Items | -1.02 | -0.84 | -0.80 | -0.74 | -0.77 |
Diluted Net EPS (GAAP) | -1.06 | -0.84 | -0.80 | -0.74 | -0.74 |